Press release
Share Of Diabetic Neuropathy Is Nearly One-Fourth And Expanding At A CAGR Of 5.6% Through 2025
Additionally, the underdiagnosis of individuals with peripheral neuropathy will increase the potential of these medications. According to projections, there will be a positive CAGR of 5.9% and a market share of more than 50%.
๐๐ผ๐๐ป๐น๐ผ๐ฎ๐ฑ ๐๐ฟ๐ฒ๐ฒ ๐ฆ๐ฎ๐บ๐ฝ๐น๐ฒ ๐๐ผ๐ฝ๐ ๐ผ๐ณ ๐ง๐ต๐ถ๐ ๐ฅ๐ฒ๐ฝ๐ผ๐ฟ๐: https://www.factmr.com/connectus/sample?flag=S&rep_id=4698?PS
Thus, it is estimated that a growth in the number of patients with proximal neuropathy will propel the development of diabetic neuropathy medications and formulations, which are expected to account for approximately one-fourth of the market share and grow at a CAGR of 5.6% through 2025.
Diabetic neuropathy formulations are expected to be used more frequently in the segment treating peripheral neuropathy disorders. The market for medications to treat peripheral neuropathy is expected to grow because present therapies for the condition focus more on pain management than on nerve regeneration.
The key market players are Arbor Pharmaceuticals, LLC, Pfizer, Inc., Janssen Global Services, LLC, NeuroMatrix, Inc., Depomed, Inc., and Eli Lilly
๐๐ฒ๐ ๐๐๐๐๐ผ๐บ๐ถ๐๐ฎ๐๐ถ๐ผ๐ป ๐ผ๐ป ๐๐ต๐ถ๐ ๐ฅ๐ฒ๐ฝ๐ผ๐ฟ๐: https://www.factmr.com/connectus/sample?flag=RC&rep_id=4698
However, it is envisaged that formulations for diabetic neuropathy would find significant applicability in proximal neuropathy problems. Among type 2 diabetics, proximal neuropathy is the most prevalent condition.
Global Diabetic Neuropathy Market Segmentation
Fact.MR has studied the global diabetic neuropathy market with detailed segmentation on the basis of disorder, treatment, distribution channel and region.
By Disorder
โข Peripheral Neuropathy
โข Autonomic Neuropathy
โข Proximal Neuropathy
โข Focal Neuropathy
By Treatment
โข Drugs
โข Analgesic
Topical:
โข Capsaicin
โข Others
Opioid:
โข Morphine
โข Others
NSAIDs:
โข Ibuprofen
โข Naproxen
โข Others
Antidepressants:
TCAs:
โข Amitriptyline
โข Imipramine
โข Others
โข SNRIs:
โข Duloxetine
โข Others
SSRIs:
โข Citalopram
โข Paroxetine
โข Others
Anticonvulsant Drugs:
โข Gabapentin
โข Pregabalin
โข Topiramate
โข Others
โข Other Drugs
By Radiotherapy:
โข Transcutaneous Electrical Nerve Stimulation (TENS)
โข Others
โข Physiotherapy
By Distribution Channel
โข Hospitals
โข Clinics
โข Retail Pharmacy
โข Online Pharmacy
By Region
โข North America
โข Europe
โข Asia Pacific
โข Latin America
โข Middle East & Africa (MEA)
During the projection period, North America is expected to experience significant consumption of diabetic neuropathy medications. The proportion of diabetic neuropathy patients receiving a diagnosis and treatment is expected to rise, and so will government spending on research into potential new treatments and medications.
The study further identifies major manufacturing trends, technologies that will be commercialized
โข Key manufacturing trends in end-use industries;
โข New technologies used in a variety of application areas
โข Key manufacturing trends in end-use industries
โข New technologies used in a variety of application areas; Major economic shocks, such as the recent COVID-19 pandemic
โข Country markets that will emerge as hotbeds of opportunity;
โข Regulatory frameworks that will shape the strategies of key players in key regions in the Diabetic Neuropathy market
โข Key technological trends and the likely rate of commercialization of novel technologies in key industries and allied industries
๐๐ฒ๐ ๐๐๐น๐น ๐๐ฐ๐ฐ๐ฒ๐๐ ๐ผ๐ณ ๐๐ผ๐บ๐ฝ๐น๐ฒ๐๐ฒ ๐ฅ๐ฒ๐ฝ๐ผ๐ฟ๐: https://www.factmr.com/checkout/4698
Contact:
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
About Fact.MR
We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Share Of Diabetic Neuropathy Is Nearly One-Fourth And Expanding At A CAGR Of 5.6% Through 2025 here
News-ID: 2886960 • Views: โฆ
More Releases from Fact.MR
Fine Blanking Tools Market Projected to Reach USD 1.43 Billion by 2035 | U.S. CA โฆ
The global Fine Blanking Tools Market is set for steady growth over the next decade, driven by rising demand for high-precision components, ongoing industrial automation, and surging requirements from automotive, electronics, and aerospace sectors. According to a recent forecast, the market is expected to grow from approximately USD 948.1 million in 2025 to USD 1,430.6 million by 2035, at a compound annual growth rate (CAGR) of about 4.2 % betweenโฆ
Benzodiazepine Drugs Market is Expanding USD 5.4 billion by 2035 | Pfizer Inc.; โฆ
The global benzodiazepine drugs market is projected to expand in the coming decade, driven by growing incidence of anxiety, insomnia, alcohol-withdrawal disorders, and advances in pharmaceutical formulations. According to a recent Fact.MR report, the market was valued at approximately USD 2.35 billion in 2022, and is expected to grow at a compound annual growth rate (CAGR) of 2.8% to reach USD 3.1 billion by 2032.
Market Drivers & Outlook
The demand forโฆ
Ultrasound Systems Market to Surge to Nearly USD 20 Billion by 2035, Led by Adva โฆ
The global Ultrasound Systems Market is on a strong growth trajectory, projected to rise from USD 10.8 billion in 2025 to approximately USD 19.7 billion by 2035, expanding at a CAGR of 6.2% during the forecast period. This growth is fueled by the rising demand for non-invasive diagnostic imaging, the increasing prevalence of chronic diseases, expanding healthcare infrastructure, and continuous technological innovations such as AI integration and portable imaging systems.
Keyโฆ
Surgical Staplers Market Is Forecasted To Reach USD 6.0 Billion In 2025 | Ethico โฆ
The global Surgical Staplers Market is forecast to show strong growth over the next decade, nearly doubling in value as demand surges for efficient, reliable wound closure in advanced surgical procedures. According to the latest Fact.MR Surgical Staplers Market Size & Share Forecast Outlook 2025-2035 report, the market is expected to grow from USD 6.0 billion in 2025 to USD 12.5 billion by 2035, at a compound annual growth rateโฆ
More Releases for Neuropathy
Neuropathy Care Centers Launches National Push to Rethink Peripheral Neuropathy โฆ
A healthcare organization builds out a collaborative model aimed at earlier intervention and improved patient understanding
WHEATON, IL - July 14, 2025 - Neuropathy Care Centers, a Wheaton-based healthcare organization, today announced the expansion of its national initiative to improve how Peripheral Neuropathy is identified and managed across the U.S. The organization is developing a growing network of providers focused on early detection and conservative, nerve-focused care, an effort intended toโฆ
Chemotherapy Induced Peripheral Neuropathy Market Trends and Insights, Toward Sa โฆ
Overview of the Market
Chemotherapy Induced Peripheral Neuropathy (CIPN) is one of the most common and debilitating side effects of cancer treatment, affecting a significant portion of chemotherapy patients. CIPN occurs when chemotherapy drugs cause damage to the peripheral nerves, leading to symptoms such as numbness, tingling, burning sensations, and pain, primarily in the hands and feet. With the growing global prevalence of cancer, the incidence of CIPN is also rising,โฆ
Prominent Diabetic Peripheral Neuropathy Market Trend for 2025: Advancements In โฆ
What industry-specific factors are fueling the growth of the diabetic peripheral neuropathy market?
The increase in obesity-related health issues is expected to drive the growth of the diabetic peripheral neuropathy (DPN) market. Obesity, characterized by excessive body fat accumulation, significantly increases the risk of chronic diseases, including type 2 diabetes. This, in turn, heightens the occurrence of diabetic peripheral neuropathy, a complication where high blood sugar levels cause nerve damage. Theโฆ
Major Market Shift in Peripheral Neuropathy Industry: Technological Advancements โฆ
What Is the Forecasted Market Size and Growth Rate for the Peripheral Neuropathy Market?
The size of the peripheral neuropathy market has seen a rapid expansion in recent years, set to increase from $4.09 billion in 2024 to $4.62 billion in 2025, representing a compound annual growth rate (CAGR) of 13.2%. This growth during the historical period is due to a variety of factors including the rising prevalence of chronic illnessesโฆ
Multifocal Motor Neuropathy Market - Progress in nerve restoration: Driving adva โฆ
Newark, New Castle, USA: The "Multifocal Motor Neuropathy Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Multifocal Motor Neuropathy Market: https://www.growthplusreports.com/report/multifocal-motor-neuropathy-market/8810
This latest report researches the industry structure,โฆ
Optic Neuropathy Management Market Rising cases of optic neuropathy and advancem โฆ
Global Optic Neuropathy Management Market Overview:
The Optic Neuropathy Management market is a broad category that includes a wide range of products and services related to various industries. This market comprises companies that operate in areas such as consumer goods, technology, healthcare, and finance, among others.
In recent years, the Optic Neuropathy Management market has experienced significant growth, driven by factors such as increasing consumer demand, technological advancements, and globalization. This growthโฆ
